Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry
NCT06412120Phase 4Recruiting
- Sponsor
- University of Miami
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, open-label, single-arm trial of niraparib in ovarian cancer, sponsored by University of Miami. Primary endpoint: Proportion of Participants Experiencing Any Grade or Grade 3 or Higher of the Most Common Adverse Events at 3 years. Started Jul 2026; status: recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT06412120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06412120.